Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ADIL 
Adial Pharmaceuticals Inc (ADIL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: ADIL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.11% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.47M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 3 | Beta 1.19 | 52 Weeks Range 0.22 - 1.37 | Updated Date 07/11/2025 |
52 Weeks Range 0.22 - 1.37 | Updated Date 07/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.87 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -107.38% | Return on Equity (TTM) -217.01% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3707939 | Price to Sales(TTM) - |
Enterprise Value 3707939 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.49 | Shares Outstanding 15775900 | Shares Floating 7846338 |
Shares Outstanding 15775900 | Shares Floating 7846338 | ||
Percent Insiders 3.41 | Percent Institutions 3.64 |
Upturn AI SWOT
Adial Pharmaceuticals Inc
Company Overview
History and Background
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for diseases of addiction. Founded in 2007, it aims to address unmet medical needs in the treatment of alcohol use disorder (AUD) and other addiction-related disorders. The company's lead product candidate is AD04, a genetically targeted therapeutic agent.
Core Business Areas
- Therapeutic Development: Focuses on the research, development, and commercialization of AD04 for the treatment of Alcohol Use Disorder (AUD).
- Genetic Testing: Incorporates a genetic test to identify patients most likely to respond to AD04, aiming for personalized treatment.
Leadership and Structure
The company has a management team led by a CEO and includes individuals with expertise in clinical development, regulatory affairs, and commercialization. The organizational structure is typical of a small, clinical-stage biotech company, with departments focused on research, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- AD04: AD04 is Adial's lead product candidate, a genetically targeted therapeutic for Alcohol Use Disorder (AUD). It is currently in Phase 3 clinical trials. Since it is in development and not yet approved, there is currently no market share or revenue to report. Key competitors include pharmaceutical companies offering alternative treatments for AUD such as naltrexone (Vivitrol, Revia), acamprosate (Campral), and disulfiram (Antabuse).
Market Dynamics
Industry Overview
The pharmaceutical industry targeting addiction is driven by a significant unmet need for effective treatments. Alcohol Use Disorder (AUD) affects millions, creating a substantial market opportunity. The industry involves various players, from large pharmaceutical companies to smaller biotechs.
Positioning
Adial is positioned as a precision medicine company using a genetic approach to treat AUD. Its competitive advantage lies in its genetically targeted approach with AD04, aiming for higher efficacy and reduced side effects compared to traditional treatments.
Total Addressable Market (TAM)
The TAM for AUD treatments is substantial. Estimates range in the billions of dollars annually, globally. Adial aims to capture a portion of this market with AD04 through its unique genetically targeted approach, which the hope is will resonate within the medical community and patients suffering from AUD
Upturn SWOT Analysis
Strengths
- Genetically targeted therapy (AD04)
- Personalized medicine approach
- Focus on unmet need in AUD treatment
- Phase 3 clinical trial stage
Weaknesses
- Reliance on a single product candidate (AD04)
- Clinical trial risks and uncertainty
- Limited financial resources
- Small company size relative to competitors
Opportunities
- Potential for FDA approval and commercialization of AD04
- Expansion into other addiction-related disorders
- Strategic partnerships with larger pharmaceutical companies
- Positive clinical trial results enhancing investor confidence
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from existing AUD treatments
- Market acceptance of genetically targeted therapies
- Funding challenges and dilution
Competitors and Market Share
Key Competitors
- TEVA
- VTRS
- ALKS
- OTCQX:SNOA
Competitive Landscape
Adial's genetically targeted approach differentiates it from competitors offering traditional pharmaceutical treatments. Its advantages lie in potentially higher efficacy and fewer side effects, but it faces challenges in terms of market acceptance and competition from established players.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by advancements in clinical trials and financing activities rather than revenue generation.
Future Projections: Future growth hinges on the successful completion of Phase 3 trials and potential FDA approval of AD04. Analyst projections vary, but positive results could lead to significant revenue growth.
Recent Initiatives: Recent initiatives include enrollment in the ONWARD Phase 3 clinical trial, and ongoing business development.
Summary
Adial Pharmaceuticals is a high-risk, high-reward clinical-stage company focused on a novel, genetically targeted approach to treating Alcohol Use Disorder. Its success is contingent upon the outcome of its ongoing Phase 3 clinical trials for AD04. The company's key strength is its innovative approach. It must carefully manage its financial resources and navigate the regulatory landscape to capitalize on the opportunities in the large and unmet market for AUD treatments. However, it remains vulnerable to clinical trial failures and competition from established treatments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Adial Pharmaceuticals Inc. SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is based on available public information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adial Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Glen Allen, VA, United States | ||
IPO Launch date 2018-07-30 | CEO, President & Director Mr. Cary John Claiborne MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.adial.com |
Full time employees 5 | Website https://www.adial.com | ||
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.